<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01115933</url>
  </required_header>
  <id_info>
    <org_study_id>09-385</org_study_id>
    <nct_id>NCT01115933</nct_id>
  </id_info>
  <brief_title>A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population</brief_title>
  <acronym>SV JAPAN</acronym>
  <official_title>SPIRIT PRIME JAPAN (SV JAPAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the AVJ-09-385 Small
      Vessel Everolimus Eluting Coronary Stent System (EECSS) (2.25 mm diameter stent) in treatment
      of subjects with ischemic heart disease caused by de novo lesions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Endpoint of Cardiac Death/TV-MI/CI-TLR (TLF)</measure>
    <time_frame>9 Months</time_frame>
    <description>Target lesion failure (TLF) is the composite of any of the following adverse events: Cardiac death, target vessel myocardial infarction (TV-MI) (per Protocol definition), Clinically indicated target lesion revascularization (CI-TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success (Lesion Based Analysis, Only for XIENCE PRIME SV)</measure>
    <time_frame>The period during an in-hospital stay of less than or equal to 7 days post index procedure.</time_frame>
    <description>Device success is achievement final in-stent residual diameter stenosis of &lt; 50% (by QCA). If adjunct treatment devices other than protocol defined device is used for target lesion treatment, malfunction of the investigational device occurring during the index procedure, are not regarded as device success. Use of a bail-out stent is still regarded as device success unless a device malfunction has occured. If QCA %DS is not available, the data is not included in analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success(Subject Base Analysis)</measure>
    <time_frame>The period during an in-hospital stay of less than or equal to 7 days post index procedure.</time_frame>
    <description>Procedure success is defined as achievement of a final in-stent diameter stenosis of &lt; 50% (by QCA) using the investigational device (AVJ-09-385), without the occurrence MACE during the hospital stay (up to 7 days if a subject still in the hospital). If QCA %DS is not available, the data is not included in analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS), In-segment, In-stent, Proximal and Distal</measure>
    <time_frame>8 months</time_frame>
    <description>IN-STENT is defined as within the margins of the stent. IN-SEGMENT is defined as within the margins of the stent and 5 mm proximal and 5 mm distal to the stent.
PROXIMAL is defined as within 5 mm of healthy tissue proximal to stent placement DISTAL is defined as within 5 mm of healthy tissue distal to stent placement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Loss (LL), In-segment, In-stent, Proximal and Distal</measure>
    <time_frame>8 months</time_frame>
    <description>LATE LOSS (LL) calculated as MINIMUM LUMEN DIAMETER [MLD] post-procedure MINUS MLD at follow-up:
In-segment Late Loss: in-segment MLD post-procedure - in segment MLD at follow-up In-stent Late Loss: in-stent MLD post-procedure - in-stent MLD at follow-up Proximal Late Loss: proximal MLD post-procedure - proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement) Distal Late Loss: distal MLD post-procedure - distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Binary Restenosis (ABR), In-segment, In-stent, Proximal and Distal</measure>
    <time_frame>8 months</time_frame>
    <description>IN-STENT is defined as within the margins of the stent. IN-SEGMENT is defined as within the margins of the stent and 5 mm proximal and 5 mm distal to the stent.
PROXIMAL is defined as within 5 mm of healthy tissue proximal to stent placement DISTAL is defined as within 5 mm of healthy tissue distal to stent placement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (Cardiac, Vascular, Non-Cardiovascular, Per ARC Definition)</measure>
    <time_frame>1 month</time_frame>
    <description>DEATH (Per ARC Circulation 2007; 115: 2344-2351)
All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (Cardiac, Vascular, Non-Cardiovascular, Per ARC Definition)</measure>
    <time_frame>9 months</time_frame>
    <description>DEATH (Per ARC Circulation 2007; 115: 2344-2351) All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions)</measure>
    <time_frame>1 month</time_frame>
    <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions)</measure>
    <time_frame>9 months</time_frame>
    <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions) Attributable to Target Vessel (TV-MI)</measure>
    <time_frame>1 month</time_frame>
    <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG
Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves
Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions) Attributable to Target Vessel (TV-MI)</measure>
    <time_frame>9 months</time_frame>
    <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions) Not Attributable to Target Vessel (NTV-MI)</measure>
    <time_frame>1 month</time_frame>
    <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions) Not Attributable to Target Vessel (NTV-MI)</measure>
    <time_frame>9 months</time_frame>
    <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR, Per ARC Definition)</measure>
    <time_frame>1 month</time_frame>
    <description>Any revascularization for in-segment restenosis will be considered TLR.&quot;Segment&quot; is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR, Per ARC Definition)</measure>
    <time_frame>9 months</time_frame>
    <description>Any revascularization for in-segment restenosis will be considered TLR. &quot;Segment&quot; is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR, Per ARC Definition) Clinically-indicated TLR (CI-TLR)</measure>
    <time_frame>1 month</time_frame>
    <description>Any revascularization for in-segment restenosis will be considered TLR. &quot;Segment&quot; is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR, Per ARC Definition) Clinically-indicated TLR (CI-TLR)</measure>
    <time_frame>9 months</time_frame>
    <description>Any revascularization for in-segment restenosis will be considered TLR. &quot;Segment&quot; is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR, Per ARC Definition) Not Clinically-indicated TLR (NCI-TLR)</measure>
    <time_frame>1 month</time_frame>
    <description>Any revascularization for in-segment restenosis will be considered TLR. &quot;Segment&quot; is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR, Per ARC Definition) Not Clinically-indicated TLR (NCI-TLR)</measure>
    <time_frame>9 months</time_frame>
    <description>Any revascularization for in-segment restenosis will be considered TLR. &quot;Segment&quot; is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR, Per ARC Definition)</measure>
    <time_frame>1 month</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR, Per ARC Definition)</measure>
    <time_frame>9 months</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR, Per ARC Definition) Clinically-indicated TVR (CI-TVR)</measure>
    <time_frame>1 month</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR, Per ARC Definition) Clinically-indicated TVR (CI-TVR)</measure>
    <time_frame>9 months</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR, Per ARC Definition) Not Clinically-indicated TVR (NCI-TVR)</measure>
    <time_frame>1 month</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR, Per ARC Definition) Not Clinically-indicated TVR (NCI-TVR)</measure>
    <time_frame>9 months</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Cardiac Death/All MI</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Cardiac Death/All MI</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>1 month</time_frame>
    <description>DMR event (all death, all MI (per protocol or per ARC), all revascularization, respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>9 months</time_frame>
    <description>DMR event (all death, all MI (per protocol or per ARC), all revascularization, respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Cardiac Death/TV-MI/CI-TLR (TLF)</measure>
    <time_frame>1 month</time_frame>
    <description>Target lesion failure (TLF) is defined as a composite of cardiac death, target-vessel related myocardial infarction (TV-MI) and clinically-indicated target lesion revascularization (CI-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Cardiac Death/All MI/CI-TLR (MACE)</measure>
    <time_frame>1 month</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial-infarction, and clinically-indicated target lesion revascularization (CI-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Cardiac Death, All MI and CI-TLR (MACE)</measure>
    <time_frame>9 months</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial-infarction, and clinically-indicated target lesion revascularization (CI-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Coronary Revascularization</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Coronary Revascularization</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Stent Thrombosis</measure>
    <time_frame>&lt;24 hours</time_frame>
    <description>Stent thrombosis (ST) was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subacute Stent Thrombosis</measure>
    <time_frame>1-30 days</time_frame>
    <description>Stent thrombosis was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute/Subacute Stent Thrombosis</measure>
    <time_frame>0-30 days</time_frame>
    <description>Stent thrombosis was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Stent Thrombosis</measure>
    <time_frame>31 - 298 days</time_frame>
    <description>Stent thrombosis was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Stent Thrombosis</measure>
    <time_frame>0 - 298 days</time_frame>
    <description>Stent thrombosis was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.&quot;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Vascular Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>XIENCE PRIME SV EECSS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XIENCE PRIME SV EECSS: Small Vessel Everolimus Eluting Coronary Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE PRIME SV EECSS</intervention_name>
    <description>Patients receiving XIENCE PRIME SV EECSS</description>
    <arm_group_label>XIENCE PRIME SV EECSS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be at least 20 years of age.

          2. Subject or a legally authorized representative must provide written informed consent
             prior to any study related procedure, per site requirements.

          3. Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina,
             silent ischemia, positive functional study or a reversible change in the
             electrocardiogram (ECG) consistent with ischemia).

          4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG)
             surgery.

          5. Subject must agree to undergo all protocol-required follow-up procedures.

          6. Subject must agree not to participate in any other clinical study for a period of one
             year following the index procedure.

        Angiographic Inclusion Criteria

          1. One (target) or two (one target and one non-target) de novo lesions each in a
             different epicardial vessel.

          2. Lesion(s) must be located in a major artery or branch with a visually estimated
             diameter stenosis of ≥ 50% and &lt; 100% with a TIMI flow of ≥ 1.

          3. Lesion(s) must be located in a native coronary artery with reference vessel diameter
             (RVD) by visual estimation of ≥ 2.25 mm and &lt; 2.5 mm.

          4. Lesion(s) must be located in a native coronary artery with length by visual estimation
             of ≤ 22 mm.

        Exclusion Criteria:

          1. Subject has had a known diagnosis of acute myocardial infarction (AMI) preceding the
             index procedure (CK-MB ≥ 2 times upper limit of normal) and CK and CK-MB have not
             returned to within normal limits at the time of procedure.

          2. The subject is currently experiencing clinical symptoms consistent with new onset AMI,
             such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes.

          3. Subject has current unstable cardiac arrhythmias associated with hemodynamic
             instability.

          4. Subject has a known left ventricular ejection fraction (LVEF) &lt; 40% (LVEF may be
             obtained at the time of the index procedure if the value is unknown and if necessary).

          5. Subject has received coronary brachytherapy in any epicardial vessel.

          6. Subject has received any organ transplant or is on a waiting list for any organ
             transplant.

          7. Subject is receiving or scheduled to receive chemotherapy for malignancy within 30
             days prior to or within one year after the index procedure.

          8. Subject is receiving or scheduled to receive planned radiotherapy to the
             chest/mediastinum.

          9. Subject is receiving immunosuppressant therapy or has known immunosuppressive or
             autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus
             etc.).

         10. Subject is receiving chronic anticoagulation therapy (e.g., heparin, warfarin).

         11. Subject will require Low Molecular Weight Heparin (LMWH) post-procedure.

         12. Subject has a known hypersensitivity or contraindication to aspirin, heparin,
             clopidogrel/ticlopidine, everolimus, cobalt, chromium, nickel, tungsten, acrylic and
             fluoro polymers or contrast sensitivity that cannot be adequately pre-medicated.

         13. Elective surgery is planned within 6 months after the procedure that will require
             discontinuing either aspirin or clopidogrel.

         14. Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3, a white blood
             cell (WBC) of &lt; 3,000 cells/mm3, or documented or suspected liver disease (including
             laboratory evidence of hepatitis).

         15. Subject has known renal insufficiency (examples being but not limited to serum
             creatinine level ≥ 2.0 mg/dL, or on dialysis).

         16. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions.

         17. Subject has had a cerebrovascular accident/stroke or transient ischemic neurological
             attack (TIA) within the past six months.

         18. Subject has had a significant gastro-intestinal or significant urinary bleed within
             the past six months.

         19. Subject has extensive peripheral vascular disease that precludes safe 5 French
             catheter insertion.

         20. Subject has other medical illness (e.g., cancer) or known history of substance abuse
             (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol,
             confound the data interpretation or is associated with a limited life expectancy
             (i.e., less than one year).

         21. Subject is currently participating in another clinical study that has not yet
             completed its primary endpoint.

         22. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
             following index procedure. Female subjects of child-bearing potential must have a
             negative pregnancy test done within 7 days prior to the index procedure per site
             standard test*.

               -  Whether a subject who met this criterion will be asked for pregnancy test will be
                  decided per site standard. However, subject enrollment in the study is not
                  allowed without pregnancy test result.

        Angiographic Exclusion Criteria All angiographic exclusion criteria are based on visual
        estimation.

          1. Target lesion located within an arterial or saphenous vein graft or distal to a
             diseased (vessel irregularity per angiogram and &gt; 20% stenosed lesion) arterial or
             saphenous vein graft.

          2. Target lesion involving a bifurcation with a side branch ≥ 2 mm in diameter and/or
             ostial lesion &gt; 40% stenosed or side branch requiring protection guidewire, or side
             branch requiring dilatation.

          3. Target lesion with total occlusion (TIMI flow 0), prior to crossing with the wire.

          4. Another lesion requiring revascularization is located in the same epicardial vessel of
             the target lesion.

          5. Restenotic lesion.

          6. Aorto-ostial target lesion (within 3 mm of the aorta junction).

          7. Lesion in the left main trunk (both target and non-target).

          8. Lesion located within 2 mm of the origin of the LAD or LCX.

          9. Extreme angulation (≥ 90 °) or excessive tortuosity (≥ two 45° angles) proximal to or
             within the target lesion.

         10. Heavy calcification proximal to or within the target lesion.

         11. Target vessel contains thrombus as indicated in the angiographic images.

         12. Target lesion has a high probability that a procedure other than pre-dilatation and
             stenting will be required at the time of index procedure for treatment of the target
             vessel (e.g. rotablator, DCA, cutting balloon).

         13. Target vessel is previously treated* with any type of PCI (e.g. balloon angioplasty,
             stent, rotablator, DCA, cutting balloon) within 9 months of index procedure.

         14. Non-target vessel was previously treated with any type of PCI within 90 days of index
             procedure.

         15. Additional clinically significant lesion(s) in the target vessel or side branch for
             which PCI may be required within 90 days after the index procedure.

               -  Target lesion must be separated ≥ 5 mm from a previously treated lesion (stenosis
                  within 5 mm of previously treated lesion is regarded as &quot;restenosis&quot;).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takaaki Isshiki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Teikyo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kita-kyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido Social Insurance Hospital Cardiovascular Center</name>
      <address>
        <city>Toyohira</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University</name>
      <address>
        <city>Tokyo</city>
        <state>Itabashi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohama City Eastern Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Sakyo-ku</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sendai Kousei Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya Daini Red Cross Hospital</name>
      <address>
        <city>Showa-ku</city>
        <state>Nagoya</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Kita-ku</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokushima Red Cross Hospital</name>
      <address>
        <city>Komatsushima</city>
        <state>Tokushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Central Hospital</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2010</study_first_posted>
  <results_first_submitted>August 6, 2013</results_first_submitted>
  <results_first_submitted_qc>November 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 3, 2014</results_first_posted>
  <last_update_submitted>July 17, 2015</last_update_submitted>
  <last_update_submitted_qc>July 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug eluting stents</keyword>
  <keyword>small vessel</keyword>
  <keyword>Stents</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 65 subjects at 15 Japanese sites were enrolled between April, 2010 and August, 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>XIENCE PRIME SV EECSS</title>
          <description>XIENCE PRIME SV EECSS: XIENCE PRIME Small Vessel (2.25 mm) Everolimus Eluting Coronary Stent System
XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive XIENCE PRIME SV</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Based on number of patients who received XIENCE PRIME SV EECSS</population>
      <group_list>
        <group group_id="B1">
          <title>XIENCE PRIME SV EECSS</title>
          <description>XIENCE PRIME SV Everolimus Eluting Coronary Stent System
XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.63" spread="7.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Endpoint of Cardiac Death/TV-MI/CI-TLR (TLF)</title>
        <description>Target lesion failure (TLF) is the composite of any of the following adverse events: Cardiac death, target vessel myocardial infarction (TV-MI) (per Protocol definition), Clinically indicated target lesion revascularization (CI-TLR)</description>
        <time_frame>9 Months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death/TV-MI/CI-TLR (TLF)</title>
          <description>Target lesion failure (TLF) is the composite of any of the following adverse events: Cardiac death, target vessel myocardial infarction (TV-MI) (per Protocol definition), Clinically indicated target lesion revascularization (CI-TLR)</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success (Lesion Based Analysis, Only for XIENCE PRIME SV)</title>
        <description>Device success is achievement final in-stent residual diameter stenosis of &lt; 50% (by QCA). If adjunct treatment devices other than protocol defined device is used for target lesion treatment, malfunction of the investigational device occurring during the index procedure, are not regarded as device success. Use of a bail-out stent is still regarded as device success unless a device malfunction has occured. If QCA %DS is not available, the data is not included in analyses.</description>
        <time_frame>The period during an in-hospital stay of less than or equal to 7 days post index procedure.</time_frame>
        <population>Intent to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success (Lesion Based Analysis, Only for XIENCE PRIME SV)</title>
          <description>Device success is achievement final in-stent residual diameter stenosis of &lt; 50% (by QCA). If adjunct treatment devices other than protocol defined device is used for target lesion treatment, malfunction of the investigational device occurring during the index procedure, are not regarded as device success. Use of a bail-out stent is still regarded as device success unless a device malfunction has occured. If QCA %DS is not available, the data is not included in analyses.</description>
          <population>Intent to Treat Population (ITT)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.48" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success(Subject Base Analysis)</title>
        <description>Procedure success is defined as achievement of a final in-stent diameter stenosis of &lt; 50% (by QCA) using the investigational device (AVJ-09-385), without the occurrence MACE during the hospital stay (up to 7 days if a subject still in the hospital). If QCA %DS is not available, the data is not included in analyses.</description>
        <time_frame>The period during an in-hospital stay of less than or equal to 7 days post index procedure.</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success(Subject Base Analysis)</title>
          <description>Procedure success is defined as achievement of a final in-stent diameter stenosis of &lt; 50% (by QCA) using the investigational device (AVJ-09-385), without the occurrence MACE during the hospital stay (up to 7 days if a subject still in the hospital). If QCA %DS is not available, the data is not included in analyses.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.48" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Diameter Stenosis (%DS), In-segment, In-stent, Proximal and Distal</title>
        <description>IN-STENT is defined as within the margins of the stent. IN-SEGMENT is defined as within the margins of the stent and 5 mm proximal and 5 mm distal to the stent.
PROXIMAL is defined as within 5 mm of healthy tissue proximal to stent placement DISTAL is defined as within 5 mm of healthy tissue distal to stent placement</description>
        <time_frame>8 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS %DS In-segment</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS %DS In-stent</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS %DS Proximal</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS %DS Distal</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis (%DS), In-segment, In-stent, Proximal and Distal</title>
          <description>IN-STENT is defined as within the margins of the stent. IN-SEGMENT is defined as within the margins of the stent and 5 mm proximal and 5 mm distal to the stent.
PROXIMAL is defined as within 5 mm of healthy tissue proximal to stent placement DISTAL is defined as within 5 mm of healthy tissue distal to stent placement</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of DS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.80" spread="10.59"/>
                    <measurement group_id="O2" value="6.11" spread="11.65"/>
                    <measurement group_id="O3" value="12.32" spread="17.03"/>
                    <measurement group_id="O4" value="14.91" spread="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Loss (LL), In-segment, In-stent, Proximal and Distal</title>
        <description>LATE LOSS (LL) calculated as MINIMUM LUMEN DIAMETER [MLD] post-procedure MINUS MLD at follow-up:
In-segment Late Loss: in-segment MLD post-procedure – in segment MLD at follow-up In-stent Late Loss: in-stent MLD post-procedure – in-stent MLD at follow-up Proximal Late Loss: proximal MLD post-procedure – proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement) Distal Late Loss: distal MLD post-procedure – distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement)</description>
        <time_frame>8 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS LL In-segment</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS LL In-stent</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS LL Proximal</title>
            <description>XIENCE PRIME SV EECSS: Patients receivingXIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS LL Distal</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Late Loss (LL), In-segment, In-stent, Proximal and Distal</title>
          <description>LATE LOSS (LL) calculated as MINIMUM LUMEN DIAMETER [MLD] post-procedure MINUS MLD at follow-up:
In-segment Late Loss: in-segment MLD post-procedure – in segment MLD at follow-up In-stent Late Loss: in-stent MLD post-procedure – in-stent MLD at follow-up Proximal Late Loss: proximal MLD post-procedure – proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement) Distal Late Loss: distal MLD post-procedure – distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement)</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.24"/>
                    <measurement group_id="O2" value="0.13" spread="0.25"/>
                    <measurement group_id="O3" value="0.08" spread="0.30"/>
                    <measurement group_id="O4" value="0.08" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Binary Restenosis (ABR), In-segment, In-stent, Proximal and Distal</title>
        <description>IN-STENT is defined as within the margins of the stent. IN-SEGMENT is defined as within the margins of the stent and 5 mm proximal and 5 mm distal to the stent.
PROXIMAL is defined as within 5 mm of healthy tissue proximal to stent placement DISTAL is defined as within 5 mm of healthy tissue distal to stent placement</description>
        <time_frame>8 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS ABR In-segment</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS ABR In-stent</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS ABR Proximal</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS ABR Distal</title>
            <description>XIENCE PRIME SV EECSS : Patients receivingXIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Binary Restenosis (ABR), In-segment, In-stent, Proximal and Distal</title>
          <description>IN-STENT is defined as within the margins of the stent. IN-SEGMENT is defined as within the margins of the stent and 5 mm proximal and 5 mm distal to the stent.
PROXIMAL is defined as within 5 mm of healthy tissue proximal to stent placement DISTAL is defined as within 5 mm of healthy tissue distal to stent placement</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="1.01" upper_limit="13.50"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="5.78"/>
                    <measurement group_id="O3" value="3.7" lower_limit="0.45" upper_limit="12.75"/>
                    <measurement group_id="O4" value="0" lower_limit="0.00" upper_limit="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death (Cardiac, Vascular, Non-Cardiovascular, Per ARC Definition)</title>
        <description>DEATH (Per ARC Circulation 2007; 115: 2344-2351)
All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS - Cardiac</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS - Vascular</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving AXIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS - Non-Cardiovascular</title>
            <description>XIENCE PRIME SV EECSS : Patients receivingXIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Death (Cardiac, Vascular, Non-Cardiovascular, Per ARC Definition)</title>
          <description>DEATH (Per ARC Circulation 2007; 115: 2344-2351)
All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death (Cardiac, Vascular, Non-Cardiovascular, Per ARC Definition)</title>
        <description>DEATH (Per ARC Circulation 2007; 115: 2344-2351) All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</description>
        <time_frame>9 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS - All Death Per ARC</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS - Cardiac Death Per ARC</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS - Vascular Death Per ARC</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS - Non-Cardiovascular Death Per ARC</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving AXIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Death (Cardiac, Vascular, Non-Cardiovascular, Per ARC Definition)</title>
          <description>DEATH (Per ARC Circulation 2007; 115: 2344-2351) All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions)</title>
        <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
        <time_frame>1 month</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS - QMI Per Protocol</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS - NQMI Per Protocol</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS - QMI Per ARC Definitions</title>
            <description>XIENCE PRIME SV EECSS : Patients receivingXIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS - NQMI Per ARC Definitions</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions)</title>
          <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions)</title>
        <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
        <time_frame>9 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS - QMI Per Protocol</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS - NQMI Per Protocol</title>
            <description>XIENCE PRIME SV EECSS : Patients receivingXIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS - QMI Per ARC</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS - NQMI Per ARC</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions)</title>
          <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions) Attributable to Target Vessel (TV-MI)</title>
        <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG
Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves
Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
        <time_frame>1 month</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS- TV-QMI Per Protocol</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS - TV-NQMI Per Protocol</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS - TV-QMI Per ARC</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS - TV-NQMI Per ARC</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions) Attributable to Target Vessel (TV-MI)</title>
          <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG
Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves
Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions) Attributable to Target Vessel (TV-MI)</title>
        <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
        <time_frame>9 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS - TV-QMI Per Protocol</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS - TV-NQMI Per Protocol</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS - TV-QMI Per ARC</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS - TV-NQMI Per ARC</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions) Attributable to Target Vessel (TV-MI)</title>
          <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions) Not Attributable to Target Vessel (NTV-MI)</title>
        <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
        <time_frame>1 month</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS Non-Target Vessel QMI Per Protocol</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS Non-Target Vessel NQMI Per Protocol</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS Non-Target Vessel QMI Per ARC</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS Non-Target Vessel NQMI Per ARC</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions) Not Attributable to Target Vessel (NTV-MI)</title>
          <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions) Not Attributable to Target Vessel (NTV-MI)</title>
        <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
        <time_frame>9 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS - NTV-QMI Per Protocol</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS - NTV-NQMI Per Protocol</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS - NTV-QMI Per ARC</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS - NTV-NQMI Per ARC</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI: QMI and NQMI, Both Per SPIRIT III Protocol and Per ARC Definitions) Not Attributable to Target Vessel (NTV-MI)</title>
          <description>Definitions in SPIRIT III Study:
Q wave MI: Development of new, pathological Q wave on the ECG Non-Q wave MI: Elevation of CK levels to &gt;=two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves Per ARC definition as published in 'Academic Research Consortium., Clinical end points in coronary stent trials: a case for standardized definitions.' Circulation 2007; 115: 2344-2351</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR, Per ARC Definition)</title>
        <description>Any revascularization for in-segment restenosis will be considered TLR.“Segment” is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
        <time_frame>1 month</time_frame>
        <population>Full analysis set (FAS) population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR, Per ARC Definition)</title>
          <description>Any revascularization for in-segment restenosis will be considered TLR.“Segment” is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
          <population>Full analysis set (FAS) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR, Per ARC Definition)</title>
        <description>Any revascularization for in-segment restenosis will be considered TLR. “Segment” is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
        <time_frame>9 months</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR, Per ARC Definition)</title>
          <description>Any revascularization for in-segment restenosis will be considered TLR. “Segment” is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR, Per ARC Definition) Clinically-indicated TLR (CI-TLR)</title>
        <description>Any revascularization for in-segment restenosis will be considered TLR. “Segment” is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
        <time_frame>1 month</time_frame>
        <population>Full analysis set (FAS) population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR, Per ARC Definition) Clinically-indicated TLR (CI-TLR)</title>
          <description>Any revascularization for in-segment restenosis will be considered TLR. “Segment” is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
          <population>Full analysis set (FAS) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR, Per ARC Definition) Clinically-indicated TLR (CI-TLR)</title>
        <description>Any revascularization for in-segment restenosis will be considered TLR. “Segment” is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
        <time_frame>9 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR, Per ARC Definition) Clinically-indicated TLR (CI-TLR)</title>
          <description>Any revascularization for in-segment restenosis will be considered TLR. “Segment” is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR, Per ARC Definition) Not Clinically-indicated TLR (NCI-TLR)</title>
        <description>Any revascularization for in-segment restenosis will be considered TLR. “Segment” is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
        <time_frame>1 month</time_frame>
        <population>Full analysis set (FAS) population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR, Per ARC Definition) Not Clinically-indicated TLR (NCI-TLR)</title>
          <description>Any revascularization for in-segment restenosis will be considered TLR. “Segment” is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
          <population>Full analysis set (FAS) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR, Per ARC Definition) Not Clinically-indicated TLR (NCI-TLR)</title>
        <description>Any revascularization for in-segment restenosis will be considered TLR. “Segment” is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
        <time_frame>9 months</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR, Per ARC Definition) Not Clinically-indicated TLR (NCI-TLR)</title>
          <description>Any revascularization for in-segment restenosis will be considered TLR. “Segment” is defined as the area within the margins of the stent and 5 mm proximal and 5 mm distal to the stent. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR, Per ARC Definition)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
        <time_frame>1 month</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR, Per ARC Definition)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR, Per ARC Definition)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
        <time_frame>9 months</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR, Per ARC Definition)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR, Per ARC Definition) Clinically-indicated TVR (CI-TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
        <time_frame>1 month</time_frame>
        <population>Full analysis set (FAS) population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR, Per ARC Definition) Clinically-indicated TVR (CI-TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
          <population>Full analysis set (FAS) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR, Per ARC Definition) Clinically-indicated TVR (CI-TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
        <time_frame>9 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR, Per ARC Definition) Clinically-indicated TVR (CI-TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR, Per ARC Definition) Not Clinically-indicated TVR (NCI-TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
        <time_frame>1 month</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR, Per ARC Definition) Not Clinically-indicated TVR (NCI-TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR, Per ARC Definition) Not Clinically-indicated TVR (NCI-TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
        <time_frame>9 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR, Per ARC Definition) Not Clinically-indicated TVR (NCI-TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. Revascularization was considered clinically indicated if there was &gt;70% diameter stenosis on angiography or &gt;50% stenosis together with a positive stress test or ischaemic symptoms.</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Cardiac Death/All MI</title>
        <time_frame>1 month</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death/All MI</title>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Cardiac Death/All MI</title>
        <time_frame>9 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death/All MI</title>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of All Death/All MI/All Revascularization (DMR)</title>
        <description>DMR event (all death, all MI (per protocol or per ARC), all revascularization, respectively).</description>
        <time_frame>1 month</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of All Death/All MI/All Revascularization (DMR)</title>
          <description>DMR event (all death, all MI (per protocol or per ARC), all revascularization, respectively).</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of All Death/All MI/All Revascularization (DMR)</title>
        <description>DMR event (all death, all MI (per protocol or per ARC), all revascularization, respectively).</description>
        <time_frame>9 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of All Death/All MI/All Revascularization (DMR)</title>
          <description>DMR event (all death, all MI (per protocol or per ARC), all revascularization, respectively).</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Cardiac Death/TV-MI/CI-TLR (TLF)</title>
        <description>Target lesion failure (TLF) is defined as a composite of cardiac death, target-vessel related myocardial infarction (TV-MI) and clinically-indicated target lesion revascularization (CI-TLR).</description>
        <time_frame>1 month</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death/TV-MI/CI-TLR (TLF)</title>
          <description>Target lesion failure (TLF) is defined as a composite of cardiac death, target-vessel related myocardial infarction (TV-MI) and clinically-indicated target lesion revascularization (CI-TLR).</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Cardiac Death/All MI/CI-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial-infarction, and clinically-indicated target lesion revascularization (CI-TLR).</description>
        <time_frame>1 month</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death/All MI/CI-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial-infarction, and clinically-indicated target lesion revascularization (CI-TLR).</description>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Cardiac Death, All MI and CI-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial-infarction, and clinically-indicated target lesion revascularization (CI-TLR).</description>
        <time_frame>9 months</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death, All MI and CI-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial-infarction, and clinically-indicated target lesion revascularization (CI-TLR).</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Coronary Revascularization</title>
        <time_frame>1 months</time_frame>
        <population>Full Analysis Set (FAS population)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>All Coronary Revascularization</title>
          <population>Full Analysis Set (FAS population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Coronary Revascularization</title>
        <time_frame>9 months</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>All Coronary Revascularization</title>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Stent Thrombosis</title>
        <description>Stent thrombosis (ST) was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.”</description>
        <time_frame>&lt;24 hours</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS - ST Definite</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS - ST Probable</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS - ST Possible</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS - ST Definite/Probable</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O5">
            <title>XIENCE PRIME SV EECSS - ST Definite/Probable/Possible</title>
            <description>XIENCE PRIME SV EECSS : Patients receivingXIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Stent Thrombosis</title>
          <description>Stent thrombosis (ST) was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.”</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subacute Stent Thrombosis</title>
        <description>Stent thrombosis was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.”</description>
        <time_frame>1-30 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS - ST Definite</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS - ST Probable</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS - ST Possible</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS - ST Definite/Probable</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O5">
            <title>XIENCE PRIME SV EECSS - ST Definite/Probable/Possible</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Subacute Stent Thrombosis</title>
          <description>Stent thrombosis was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.”</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute/Subacute Stent Thrombosis</title>
        <description>Stent thrombosis was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.”</description>
        <time_frame>0-30 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS - ST Definite</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS - ST Probable</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS - ST Possible</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS - ST Definite/Probable</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O5">
            <title>XIENCE PRIME SV EECSS - ST Definite/Probable/Possible</title>
            <description>XIENCE PRIME SV EECSS: Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Acute/Subacute Stent Thrombosis</title>
          <description>Stent thrombosis was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.”</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Stent Thrombosis</title>
        <description>Stent thrombosis was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.”</description>
        <time_frame>31 - 298 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS - ST Definite</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS- ST Probable</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS - ST Possible</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS - ST Definite/Probable</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O5">
            <title>XIENCE PRIME SV EECSS - ST Definite/Probable/Possible</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Late Stent Thrombosis</title>
          <description>Stent thrombosis was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.”</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Stent Thrombosis</title>
        <description>Stent thrombosis was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.”</description>
        <time_frame>0 - 298 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV EECSS - ST Definite</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME SV EECSS - ST Probable</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O3">
            <title>XIENCE PRIME SV EECSS - ST Possible</title>
            <description>XIENCE PRIME SV EECSS: Small Vessel Everolimus Eluting Coronary Stent System
XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O4">
            <title>XIENCE PRIME SV EECSS - ST Definite/Probable</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
          <group group_id="O5">
            <title>XIENCE PRIME SV EECSS - ST Definite/Probable/Possible</title>
            <description>XIENCE PRIME SV EECSS : Patients receiving XIENCE PRIME SV EECSS</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Stent Thrombosis</title>
          <description>Stent thrombosis was defined according to the ARC guidelines as follows: definite: acute coronary syndrome and angiographic or pathological confirmation of ST; probable: unexplained death ≤30 days or target vessel MI without angiographic information; and possible: unexplained death &gt;30 days after stent placement.”</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Nine (9) month post procedure data which includes events which occurred up to 298 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AVJ-09-385 SV EECSS</title>
          <description>SV EECSS: Small Vessel Everolimus Eluting Coronary Stent System
AVJ-09-385 EECSS : Patients receiving AVJ-09-385 EECSS</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Not specified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Not specified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Not specified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>hordeolum, influenza, nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David R Rutledge</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>(408) 845-3820</phone>
      <email>david.rutledge@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

